Literature DB >> 2223246

FcR-mediated enhancement of HIV-1 infection by antibody.

A Takeda1, F A Ennis.   

Abstract

Although CD4 is a major receptor for human immunodeficiency virus (HIV) infection of cells, studied by ourselves and others clearly show that the Fc receptor (FcR) also plays a role in infection, perhaps in conjunction with other surface receptors. IgG antibodies to HIV-1 will enhance infectivity in cells (such as monocyte-macrophages) that have surface Fc receptors; F(ab')2 fragments of antibodies did not enhance, and blocking of FcR inhibited enhancement. The high-affinity FcR for IgG (Fc gamma RI) appeared to be functional. Sera from HIV-1-infected patients had neutralizing activity at high concentrations, but enhanced infection at low concentrations (i.e., high dilutions). Our studies show that the CD4 receptor is required for antibody-mediated enhancement of infection, as enhancement can be blocked by recombinant soluble CD4 and by Leu3 antibody. Although enhancement can be demonstrated in vitro, the in vivo importance of enhancing antibodies remains to be defined in HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2223246     DOI: 10.1089/aid.1990.6.999

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  13 in total

1.  Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251.

Authors:  Johannes S Gach; David Venzon; Monica Vaccari; Brandon F Keele; Genoveffa Franchini; Donald N Forthal
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

2.  Predictors of survival in human immunodeficiency virus type 1-seropositive intravenous drug users.

Authors:  J B Page; S Lai; M A Fletcher; R Patarca; P C Smith; H C Lai; N G Klimas
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

3.  Effect of immunoglobulin G isotype on the infectivity of Chlamydia trachomatis in a mouse model of intravaginal infection.

Authors:  E M Peterson; X Cheng; V L Motin; L M de la Maza
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

4.  The engagement of activating FcgammaRs inhibits primate lentivirus replication in human macrophages.

Authors:  Annie David; Asier Sáez-Cirión; Pierre Versmisse; Odile Malbec; Bruno Iannascoli; Florence Herschke; Marianne Lucas; Françoise Barré-Sinoussi; Jean-François Mouscadet; Marc Daëron; Gianfranco Pancino
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

5.  Human retinal microglia express candidate receptors for HIV-1 infection.

Authors:  V T Pham; L Wen; P McCluskey; M C Madigan; P L Penfold
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

6.  Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus.

Authors:  W V Corapi; C W Olsen; F W Scott
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

7.  V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1.

Authors:  S C Kliks; T Shioda; N L Haigwood; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

Review 8.  Reassessment of the impact of mucosal immunity in infection with the human immunodeficiency virus (HIV) and design of relevant vaccines.

Authors:  J Mestecky; S Jackson
Journal:  J Clin Immunol       Date:  1994-09       Impact factor: 8.317

9.  Effects of antibody isotype and host cell type on in vitro neutralization of Chlamydia trachomatis.

Authors:  E M Peterson; X Cheng; S Pal; L M de la Maza
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

10.  Antibody-dependent enhancement of HIV-1 infection in human term syncytiotrophoblast cells cultured in vitro.

Authors:  F D Tóth; P Mosborg-Petersen; J Kiss; G Aboagye-Mathiesen; M Zdravkovic; H Hager; J Aranyosi; L Lampé; P Ebbesen
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.